In Silico Modeling of Ligand Molecule for Target Protein in Diabetes Mellitus Type II Insight Mechanism

Surya Prakash Dwivedi¹, Neeraja Dwivedi¹, R.B. Singh², A. Srivastav³ and Sanjay Mishra¹*

¹Department of Biotechnology, College of Engineering & Technology, IFTM Campus, Moradabad-244 001 (U.P.) India
²Halberg Hospital and Research Institute, Civil Lines Moradabad 244 001 (U.P.) India
³Laboratory of Biomedical Engineering, College of Engineering & Technology, IFTM Campus, Moradabad 244 001 (UP), India

Abstract: Type II Diabetes Mellitus or Non-Insulin dependent Diabetes mellitus (NIDDM) is one of the common diseases worldwide and often recognized as life style disease. The major symptom of this disease is an increase in blood glucose level resulting in polydypsia, polyuria and polyphagia. The cause of this abnormality is either lack of insulin production or insensitivity to the insulin produced inside the body. Glucagon like peptide (GLP) produced by the glucagons gene is responsible for insulin secretion. Thus proper functioning of GLP can be a remedy for Type II Diabetes mellitus. DiPeptidyl Peptidase IV (DPPIV) checks the GLP, thus in order to restore the normal functioning of these, the activity of DPP IV has to be checked using DPP IV inhibitors. In this paper the target sequence was retrieved, modeled using modeller 8v1 followed by validation by PROCHECK. Ligand molecule was constructed by LIGBUILDER. Docking was carried out with methylamine as a lead molecule and DPPIV as receptor to design a drug molecule. Designing of a drug molecule was followed by screening for its activity and drug likeness. The present studies provide new insights for efficient inhibition of DPP IV to restore the normal activity of the body overcoming the negative effects left by other drugs.

Keywords: Diabetes, Glucagon like peptide, DiPeptidyl Peptidase IV, Drug, Ligbuilder, Molinspiration, Osiris.

INTRODUCTION

Diabetes mellitus type 2 (Non insulin-dependent diabetes (NIDDM), obesity related diabetes, or adult-onset diabetes) is a metabolic disorder that is primarily characterized by insulin resistance, relative insulin deficiency, and hyper-glycemia [1]. It is often managed by engaging in exercise and modifying one’s diet. Diabetes mellitus type 2 is often associated with obesity and hypertension and elevated cholesterol (combined hyperlipidemia), and with the condition Metabolic syndrome (also known as Syndrome X, Reavan’s syndrome, or CHAOS). It is also associated with acromegaly, Cushing’s syndrome and a number of other endocrinological disorders.

It is rapidly increasing in the developed world, and there is some evidence that this pattern will be followed in much of the rest of the world in coming years. The body requires energy in form of ATP to perform its regular metabolism efficiently this energy is stored in carbohydrates and glucose. When the energy is required, the stored energy is released via various pathways and chemical reactions. Thus, proper storage and usage of glucose is required in proper body functioning. When the glucose metabolism in the body is disturbed leading to an alteration in the glucose level, the resulting disease is Diabetes. About 55 percent of type 2 are obese [2]. Chronic obesity leads to increased insulin resistance that can develop into diabetes, most likely because adipose tissue is a (recently identified) source of chemical signals (hormones and cytokines). Other research shows that type 2 diabetes causes obesity [3].

Glucagon like peptide is used for proper regulation of the insulin hormone for efficient usage and storage of the Glucose. Thus in order to efficiently control the glucose level in blood GLP expression has to be regulated. GLP-1 directly stimulates glucose-dependent insulin secretion via an increase in β-cell cAMP, through both protein kinase A-dependent and independent mechanisms, with activation of signalling through small G proteins contributing to control of insulin exocytosis. GLP-1 receptor (GLP-1R) activation also promotes calcium mobilization and closure of the ATP-sensitive KATP channel [4]. GLP 1 also stimulates beta cell proliferation. These observations raise the possibility that GLP-1 may be able to preserve or restore deteriorating β-cell function in type 2 diabetes in part via islet regeneration and augmentation of functional β-cell mass [5].

Dipeptidyl peptidase is used to check Glucagon like peptide over expression this helps to check the insulin secretion in turn. The principal known peptide substrates considered major targets of DPP-IV inhibitors when used for the treatment of diabetes are GLP-1 and GIP [6].

The inhibitor valine pyrrolidide (Val-pyr) reduced porcine plasma DPP-IV activity by > 90% and decreased the
degradation of intact GLP-1, both in the fasted state and following exogenous GLP-1 administration. Infusion of glucose together with GLP-1 in the presence of Val-pyr produced a significant augmentation in levels of plasma insulin compared to GLP-1 infusion in the absence of the inhibitor. The DPP-IV inhibitor isoleucine thiazolidide (Ile-thiazolidide) prevented N-terminal degradation of both GLP-1 and GIP in human serum, and oral administration of Ile-thiazolidide to both lean and obese Zucker fatty rats inhibited plasma DPP-IV activity, decreased glycaemic excursion and enhanced levels of circulating insulin following oral glucose loading. In contrast, administration of the inhibitor alone without concomitant glucose loading had no effect on levels of fasting glucose or insulin in obese Zucker rats [7]. More recent studies have examined the effects of chronic DPP-IV inhibitor administration in rodent models of type 2 diabetes. Oral administration of P32/98, 20 mg/kg b.i.d. for 3 months was associated with a progressive improvement in fasting glucose over the 12-week study period, in association with enhanced levels of glucose-stimulated insulin, a 12.5% decrease in relative body weight gain and improvements in insulin sensitivity as assessed at the end of the treatment period [8-12]. Pleiotropic functions of DPP-IV, acting as both a membrane bound and soluble form and exerting diverse effects on lymphocyte signaling, cell migration and proliferation, at times independent of its enzymatic activity, provide further challenges for scientists seeking to understand how specific inhibition of enzymatic function may impact the non-enzymatic biological actions of DPP-IV in different human tissues [13-15].

The conventional drug discovery approach is based on hit and trial methods and is often very time consuming. In addition to this; it may not lead to very efficient drugs necessarily. These shortcomings of this approach gave way to much faster and efficient method, the in silico drug designing. This approach makes use of the computed analysis of the target and various 3 dimensional possibilities of a particular structure. Not only does it make use of biology but also combines physics and chemistry involved for a drug formation. Fusion of various parameters leads to development of precise drugs and the process is precipitated with the use of computers. Also, the in silico process at the front end of lead discovery enables the pre-processing of compounds to detect their efficacy and characteristics. The approach used in this study is structure based making use of the structure of the ligand. Through this study we tried to design an inhibitor that would have least side effects and give maximum benefits overcoming the harms left by current day medicines as that of Metformin.

**METHODOLOGY**

**Comparative Protein Structure Modeling**

The sequence of the protein encoding for the disease (Diabetes Mellitus type 2) was retrieved from protein database of NCBI (http://www.ncbi.nlm.nih.gov/), (accession number CAAA43118). The similarity search was performed by protein-protein blast with the Insight/ Homology module and adjusted to align key conserved residues [16]. The maximum similarity with 99% identity was observed with pdb2BGRA chain A, crystal structure of Hiv-1 tat derived Nonapeptides tat (1-9) bound to the active site of Dipeptidyl Peptidase Iv (Cd26) 766 amino acid sequence. The 3D structure of the target protein was deduced employing the method of Threading and Fold Recognition method [17]. The modeling of 3D structure of protein encoding for the disease (Diabetes Mellitus type 2) following a stepwise procedure, was initiated with a template structure search from Protein databank (PDB) (http://www.rcsb.org/pdb/) related to the target sequence employing position-specific iterative BLAST (PSI-BLAST) [18]. From a number of hits, a potential template structure (PDB-ID: 1K30) representing the structure of Hiv-1 tat derived Nonapeptides tat was taken as template for model building.

For procedureing of fold assessment the sequence from the protein encoding for the disease (Diabetes Mellitus type 2) was submitted to the mGenThreader Server [19]. The server returned only one significant hit (PDB ID: 1K30) representing the structure of Hiv-1 tat derived Nonapeptides tat.

**Modeling of Protein Encoding for the Disease (Diabetes Mellitus Type 2)**

The template (1K30) and target sequence were aligned using mGenThreader Server [19]. After careful examination for the potential alignment errors, the automated comparative protein modeling program MODELLER 9v2 (http://salilab.org/modeller) was employed to build the model. The statistical verification of the model was evaluated with PROCHECK.

**Active Sites Prediction and Probe Sphere Using PASS**

PASS was used for the prediction and visualization of the protein binding pockets [20]. The final protein structure selected after the analysis and validation step was used as an input in pdb format. Deep view was used to view these generated files to make the further process easier. ASPS file and PROBES file were used to find the amino acid residue with minimum distance position from the active site.

**Virtual Screening of the Lead**

Lead molecule was selected for the generation of the drug. Methyl amine was used as the lead molecule. ChemSketch was used to design the drug molecule on computer to define its molecular structure.

**RIGID DOCKING**

Hex 4.5 was used for the purpose of docking of the lead with the target molecule [21]. The protein and the ligand were opened in the HEX and ligand was attached to the residue on the minimum distance position to the active site position. The docking controls were activated. The ligand was hence docked to the receptor protein. After docking was completed the position was saved in PDB format for the sub sequent steps.

**Generation and Optimization of Ligand**

Ligbuilder was used for generation of the ligands. It builds up ligand step by step using a library of organic fragments. The docked complex was provided as an input to the ligbuilder for the first step i.e. pocket generation [22]. This generated three important results: the pocket, the grid and the pharmacaphore. The results from the pocket
generation i.e. pocket and the grid and the Sybyl mol2 format of the ligand were given as an input. The populations and the ligands file in lig format was generated as the result. The result contained 5 ligands that were suitable for the conditions of a good ligand. Auto dock was used to predict the binding pattern of small molecules to the receptor of known 3D structure. It generally consists of 3 separate programs: auto dock performs the docking of the ligand to a set of grids describing the target protein; Auto grid is used for the pre calculation of these grids, and Auto tors sets up the bond that have to be treated as rotatable bonds in the ligand.

**RESULTS AND DISCUSSION**

**Target Sequence Retrieval**

The sequence of the protein encoding for dipeptidyl peptidase iv [Homo sapiens] with accession number CAA43118 was retrieved from NCBI. The similarity search was performed by protein-protein blast. The maximum similarity with 99% identity was observed with pdb2BGRA Chain A, Crystal Structure Of Hiv-1 Tat Derived Nonapeptides Tat (1-9) Bound To The Active Site Of Dipeptidyl Peptidase Iv (Cd26). The comparative 3d modeling of protein structure was performed by modeller 8vl. The modeller generated 5 models and the best model was validated and statistically analyzed by structure analysis and validation server (SAVS) [23]. The structures submitted were validated and the structure with core value of 90.6% and Zero bad contacts was used for the further process at lead target prediction. The model generated was visualized by Deep view and SPDv, which gave the idea of the 3 dimensional configuration of the protein, generated (Figs. 1A-1C).

The binding pattern, analyzed by AUTODOCK is used to predict of small molecule to the receptors of known 3D structure. The ligand and target protein were given as input and the docking was performed (Fig. 4).

After designing the drug molecule it was then screened for its activity and its drug likeness. Web based tools like MOLINSPIRATION and OSIRIS property explorer were used for this purpose. MOLINSPIRATION uses sophisticated Bayesian statistics to compare structures of representative ligands active on the particular target with structures of inactive molecules and to identify substructure features (which in turn determine physicochemical properties) typical for active molecules. Osiris draw chemical structures and calculates on-the-fly various drug-relevant properties whenever a structure is valid. Prediction results are valued and color coded. Properties with high risks of undesired effects like mutagenicity or a poor intestinal absorption are shown in red. Whereas a green color indicates drug-conform behavior.

---

**Fig. (1A).** Second predicted model generated by modeller (ribbon structure).

The final protein structure selected after the analysis and validation step was used as input in PDB format. Deep View was used to view the regenerated files.

The protein and ligand were open in HEX and ligand was attached to the residue on the minimum distance position to the active site position (Figs. 2A, 2B). The ligand was hence docked to the receptor protein.

The ligbuilder tool was used for the inhibitor generation (Fig. 3). The result contained 5 ligands and a good ligand with suitable conditions was chosen.

**Fig. (1B).** The Active site point (blue) where the ligand molecules can bind and develop into an efficient drug.

**Fig. (1C).** The 3D cavities around Probes (blue) where ligand binds.
CONCLUSION

Diabetes now occupying a major segment of common man’s ailments has traveled a long way from the first incidence of its occurrence. However, a permanent solution to the problems generated by it has not yet been reported. The major challenge on the way is the pleiotropic nature of DPP IV which can be a negative factor in its efficient incorporation as a drug. However, resolving this problem, there are not much hurdles to overcome in the process of Diabetes control. Thus with many problems still in hand to resolve, DPP IV inhibition serve as a milestone in controlling and eradication of TYPE 2 Diabetes mellitus. Moreover, this type of drug does not appear to have any side effect in the long run. Drugs as that of Metformin (biguanide) and sulphonyl ureas provided with some control of the disease however, the negative effects left behind by these drugs give them a weaker stand. DPP IV inhibition is an entirely different kind of approach trying to normalize the function of the body’s natural glucose level controllers; hence they are more promising with lesser side effects and reactions.

In order to make a contribution we tried to design a drug that would have fewer side effects compared to that with the currently available ones. Using In silico drug designing, the drug created has immense potential based on In silico parameters. Using structure based drug approach, the drug designed in this paper was developed using methylamine as a lead molecule. The results obtained by employing OSIRIS property explorer and MOLINSPIRATION project the generated molecule as a potential drug molecule with a drug score of 0.83. The drug (3-[3-(methyl amino) cyclopentyl] pentane-1,2-diol) is observed to be non-mutagenic, non-irritant, non carcinogenic, non reproductive and a low molecular weight drug which means that may lead to an easy mobilization and rather higher bioavailability.
ACKNOWLEDGEMENT

An institutional research promotion grant to the Department of Biotechnology, College of Engineering and Technology, Moradabad, U.P., India is acknowledged. The authors are grateful to Prof. R. M. Dubey (Managing Director, CET, IFTM, Moradabad, U.P, India) for providing the necessary facilities and encouragement. The authors are also thankful to Prof. B.N. Basu (Dean, Academics) and Prof. B.N. Kaul (Dean, Administration), College of Engineering and Technology, Moradabad, U.P., India, for their generous help and suggestions during the course of experimental work.

REFERENCES


Received: September 05, 2009 Revised: December 20, 2009 Accepted: December 21, 2009

© Dwivedi et al.; Licensee Bentham Open.
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.